Drug combination for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of three medications—chidamide, camrelizumab, and apatinib—for people with advanced esophageal cancer. The goal is to see if this combination can help control the cancer and potentially improve outcomes for patients who have received prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell carcinoma that is either locally advanced or has spread to other parts of the body.
- You have had 1 to 3 prior treatments for your advanced cancer. If you had immunotherapy, you were on that treatment for more than 6 months.
- You have at least one tumor that can be measured on scans, and you are able to care for yourself (ECOG score 0-1).
- Your blood counts and organ functions (heart, liver, kidneys, and thyroid) are within acceptable ranges.
- You have never taken HDAC inhibitors (like chidamide) or anti-angiogenic drugs (like apatinib), and you do not have certain health conditions such as uncontrolled bleeding, blood clots, serious heart issues, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests a combination of two drugs (cadonilimab and anlotinib) followed by radiation therapy for esophageal cancer that has returned or spread. The goal is to see if this approach helps shrink tumors and control the disease.
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.